Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2013OC127 Principal Investigator Tolar, Jakub
Phase NA
Age Group Both Scope Local
Secondary Protocol No. MT2013-34C
Title MT2013-34C: Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia: Standard of Care Considerations
Objective ENDPOINTS Specific transplant related endpoints include incidence of: neutrophil engraftment at day 42 and platelet engraftment at 1 year regimen related morality at 100 days acute GVHD at 100 days chronic GVHD at 6 months and 1 year secondary malignancies
Description This is a treatment study using a fludarabine-based preparative regimen followed by a related or unrelated allogeneic hematopoietic stem cell transplant. Three different preparative regimens are included based on disease and donor type.
Key Eligibility Diagnosis of Dyskeratosis Congenita OR Severe Aplastic Anemia with evidence of BM failure
Applicable Disease Sites Other Hematopoietic
Therapies Involved Blood and Marrow Transplant
Drugs Involved Alemtuzumab (Campath)
Anti-Thymocyte Globulin - Rabbit (ATG)
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
FLUDARABINE (FLUDARA)
Total Body irradiation (TBI)
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Non-Cancer Therapeutic
Contact Timothy Krepski Phone:612-273-2800
Email:tkrepsk1@fairview.org
Kim Nelson Phone:
Email:knelso62@fairview.org